CA2518318A1 — Histone deacetylase inhibitors
Assigned to Takeda California Inc · Expires 2004-09-30 · 22y expired
What this patent protects
Compounds that may be used to inhibit histone deacetylase having the formula (I) or formula (II) wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substit…
USPTO Abstract
Compounds that may be used to inhibit histone deacetylase having the formula (I) or formula (II) wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.
Drugs covered by this patent
- Zolinza (VORINOSTAT) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.